The Brave New World - What Can We Realistically Expect to Achieve Through Cancer Control Early in the New Millenium?

Chronic Diseases in Canada

Volumn 20, Issue 4, 1999, Pages 139-150

  Miller, Anthony B ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer; Control; Prevention; Projections; Screening

Indexed keywords

ADULT; ARTICLE; CANADA; FEMALE; FORECASTING; HUMAN; INCIDENCE; MALE; MASS SCREENING; MORTALITY; NEOPLASM;

ADULT; CANADA; FEMALE; FORECASTING; HUMANS; INCIDENCE; MALE; MASS SCREENING; MORTALITY; NEOPLASMS;

EID: 0033255642     PISSN: 02288699     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. World Health Organization. National cancer control programmes. Policies and managerial guidelines. Geneva: WHO, 1995.
2. Tomatis L, Aitio A, Day NE, Heseltine E, Kaldor J, Miller AB, et al, eds. Cancer: causes, occurrence and control. Lyon: International Agency for Research on Cancer, 1990; IARC Scientific Publications No 100.
3. Miller AB. Planning cancer control strategies. Chronic Dis Can 1992;13(1 Suppl): S1-S40.
4. Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography. A meta-analysis. JAMA 1995;273:149-54.
5. Alexander FE, Anderson TJ, Brown HK, et al. 14 years of follow-up from the Edinburgh randomised trial of breast cancer screening. Lancet 1999;353:1903-8.
6. Miller AB, To T, Baines CJ, Wall C. The Canadian national breast screening study: update on breast cancer mortality. J Natl Cancer Inst Monographs 1997;22:37-41.
7. Gastrin G, Miller AB, To T, et al. Incidence and mortality from breast cancer in the Mama program for breast screening in Finland, 1973-1986. Cancer 1994;73:2168-74.
8. Harvey BJ, Miller AB, Baines CJ, Corey PN. Effect of breast self-examination techniques on the risk of death from breast cancer. Can Med Assoc J 1997;157:1205-12.
9. Miller AB, Baines CJ, To T, Wall C, et al. Canadian national breast screening study: 2. Breast cancer detection and death rates among women age 50-59 years. Can Med Assoc J 1992;147:1477-88.
10. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 1971;215:1777-85.
11. Miller AB. Screening for cancer: is it time for a paradigm shift? Ann R Coll Physicians Surg Can, 1994;27:353-5.
12. Holowaty P, Miller AB, Rohan T, To T. The natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
13. National Cancer Institute Workshop. The 1998 Bethesda system for reporting cervical/vaginal cytological diagnoses. JAMA 1989;262:931-4.
14. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
15. Kronborg O, Fenger C, Olsen J, et al. Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
16. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-71.
17. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7.
18. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
19. Hankey BF, Feuer EJ, Limin XC, et al. Cancer surveillance series: interpreting trends in prostate cancer - part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24.
20. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer - part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999;91:1025-32.
21. Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer - part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999;91:1033-9.
22. The International Prostate Screening Trial Evaluation Group. Rationale for randomised trials of prostate cancer screening. Eur J Cancer 1999;35:262-71.
23. Chu KC, Tarone RE, Chow W-H, et al. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst 1994;86:997-1006.
24. Miller AB. Recent trends of lung cancer mortality in Canada. Can Med Assoc J 1977;116:28-30.
25. Ponten J, Adami HO, Bergstrom R, et al. Strategies for global control of cervical cancer. Int J Cancer 1995;60:1-26.
26. Quinn M, Babb P, Jones J, et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. Br Med J 1999;318;904-8.
27. Rothman N, Cantor KP, Blair A, et al. A nested case-control study of non-Hodgkin lymphoma and serum organochlorine residues. Lancet 1997;350:240-4.